Autosomal Recessive DisorderCAGEMNCT03449225
Prenatal Computer-Aided Genetics Education Module
A study testing Computer-Aided Genetic Education Module in people with Autosomal Recessive Disorder and Aneuploidy, run by Wayne State University at 1 site in United States.
Trial summary
A standard part of obstetrical care is offering prenatal genetic screening. Numerous professional guidelines have emphasized the importance of pretest counseling for prenatal genetic screenings. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Autosomal Recessive Disorder, Aneuploidy
- What is being tested?
- Computer-Aided Genetic Education Module
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Mar 2018to 31 Dec 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Pregnant with gestational age of less than 24 weeks
- Good understanding of spoken English
Who cannot join
- Known history of genetic disorder
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Hutzel Women's Hospital
Detroit, Michigan, 48201
Manesha Putra, MD, 773-241-9231, manesha.putra@gmail.com
About this study
Official title: Development of a Computer-Aided Genetics Education Module (CAGEM) on Screening and Testing for Fetal Chromosome Conditions and Carrier Status: A Clinical Trial
A standard part of obstetrical care is offering prenatal genetic screening. Numerous professional guidelines have emphasized the importance of pretest counseling for prenatal genetic screenings. Informed consent includes the optional nature of the test, information on the conditions being screened, possible test results, implication of each result, and the type of test offered (screening or diagnostic). This responsibility falls on the physician in a busy clinic. Technology may be able to address this limitation and give consistent pretest counseling for patients waiting for their appointment. This study is looking to evaluate the use of computer-aided genetics education module for facilitating decision making about prenatal genetic screening and testing for fetal chromosome conditions and carrier status.
Read the detailed description
Rationale Cytogenetic abnormalities are present in nearly 1% of live births, in approximately 2% of pregnancies in women older than 35 years who undergo prenatal diagnosis, and in fully half of all spontaneous, first-trimester abortions. Genetic counseling and screening for cytogenetic abnormalities are an integral part of routine obstetrical care. There are various screening options and strategy available commercially, including screening for the fetus and parental carrier screening. Currently American College of Obstetrics and Gynecology (ACOG) recommends that all pregnant women should be offered screening for fetal aneuploidy. ACOG also recommends panethnic screening for cystic fibrosis, hemoglobinopathies and spinal muscular atrophy carrier status. For other conditions, glycogen storage diseases and fragile X syndrome, the recommendation currently is to screen based on ethnicity and family history. Without thorough counseling, pregnant women may accept multiple screenings without considering the downstream consequences, including anxiety created by additional, sometimes uncertain, information.
Numerous professional societies guidelines have emphasized the importance of pre-test counseling in this setting due to the delicate and complicated nature of genetic conditions. Along with these guidelines, typically minimal recommended information to be provided during a pre-test counseling was included. Generally it involves, the optional nature of the test, general information about condition tested, nature of testing (screening, carrier screening or diagnostic), testing options, possible testing result, implication of each result, cost and availability of genetic counseling should needed. The responsibility of offering these tests and to perform pre-test counseling lie primarily on the obstetrical care providers and has become more burdensome as the number of testing options expands and also due to limited time for discussion during a prenatal care.
Technology may be able to address these limitations. Various studies have evaluated the use of Computerized Decision Aids (CDAs) in facilitating high-quality decision making in various health related contexts with promising results (17-20). CDAs are generally superior to traditional decision aids such as, paper-based or video-based, due to the possibility to tailor CDAs based on the information provided, the ease of information dissemination and also their interactive features which reinforce participation. This study is looking to evaluate the use of computer-based pre-test education for prenatal cytogenetic abnormalities screening.
Statement of Problem Per professional society guidelines, all women should be offered prenatal screening and/or diagnostic testing for fetal aneuploidy (chromosome conditions such as Down syndrome, trisomy 18, trisomy 13, and sex chromosome abnormalities) during pregnancy. Women should also be offered population-based carrier screening but have the option of expanded carrier screening as well. There are an increasing number of testing and screening options available during pregnancy. The obstetrics provider is primarily responsible for ensuring patients are informed about their options and the benefits, risks, and limits of each. These discussions can be time intensive in a setting where the time available is often limited. As such, there is a need to find alternate ways to educate women about their prenatal testing and screening options.
Objectives The overarching purpose of the full project is to determine whether a computer aided genetics education module can improve pregnant women's knowledge about their options for fetal aneuploidy (chromosome) screening and testing and carrier screening and facilitate informed decision making.
The specific aims of the current study are to:
- To develop a computer-aided genetics education module for prenatal cytogenetic abnormalities screening and testing and carrier screening
- To determine the acceptability of the computer-aided genetics educational module for women presenting for care in an obstetrics clinic
- To determine the feasibility of using the computer-aided genetics educational module in a busy obstetrics clinic
- To assess whether use of the module increases knowledge and enhances informed decision making
- To compare the effectiveness of the computer-aided education module to standard care in terms of knowledge gained and impact on decision making
This study will be done in two phases. Phase 1 will involve evaluating the acceptability of the computer-aided genetics education module. Changes will be made to the module based on the feedback obtained. The revised module will then be used for Phase 2. Phase 2 will involve comparing the effectiveness of the computer-aided genetics education module to standard care.
Methodology
A clinician who has access to the daily clinic patient list will identify patients eligible to participate in the study and notify an onsite study team member. Eligible study participants will then be approached by one of the study team members (either a genetic counselor, a genetic counseling student, a medical student, or a maternal-fetal medicine fellow) and be invited to participate in the study. The potential participant will be given the study information sheet and the study team member will review it with her. If the approached participant agrees to take part, participant will be randomized into one of the two arms of the study-control versus tests arm. Randomization will be performed using Qualtrics platform.
- Control arm: The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables. Once the post-education survey is completed, the participant will be given a $5 gift card for her time. Participation in the study is then complete.
- Test arm: The participant she will be given a digital device on which to access the computer-aided genetics educational module. Prior to accessing the module, the participant will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
- All responses (control and test) will be recorded using a unique participant identification number in order to pair pre- and post-intervention responses. The identifier will not be linked to any identifiable information. Of note, all subjects will receive standard provider counseling after completion of the study module (standard of care).
Phase 1: During Phase 1, The investigators will assess the acceptability of the computer-aided genetics educational module in our target study population. During this initial phase, The investigators will only be doing the test arm of the study. Quantitative and qualitative responses from the pre- and post-surveys will be obtained from batches of 10 samples; the module will then be optimized based on the qualitative feedback and overall results on the knowledge, acceptability, and informed consent questions. This will be repeated until user acceptability reaches 80% of the maximum score.
The computerized educational module has been developed based on counseling points recommended by the American College of Obstetrics and Gynecology and is based on a previous study investigating computer-aided education. The application can be accessed at https://interva-online.mobi/CAGEM/participant/guestLogin.do?packageId=178
Survey Instruments There are three separate survey instruments, all of which have been developed on the Qualtrics survey platform. The pre-education survey instrument is the same for control and test participants and includes basic knowledge questions about genetic testing and screening for chromosome conditions and carrier status. The questions are based on the standard information that should be presented when providing genetic counseling on these topics.
There are two versions of the post-intervention survey. Both versions include knowledge questions (same as pre-test questions) and demographic questions. The surveys differ in that the survey for those taking part in the test arm include questions about the acceptability of the computer-aided genetics educational module.
- Conditions
- Autosomal Recessive Disorder, Aneuploidy
- Being tested
- Computer-Aided Genetic Education Module
- Medical subject headings
- Aneuploidy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Computer-Aided Genetic Education ModuleOther
Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
| Study group | Role | What they receive |
|---|---|---|
| Control Arm | No intervention | The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables. |
| Test Arm | Experimental | • The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables. Receives: Other: Computer-Aided Genetic Education Module |
What is being measured
The primary outcome is the main question the study is designed to answer.
Knowledge of Genetics
Survey will be used to assess subjects' knowledge on prenatal genetics
Measured: Participant will be assessed from the time of randomization and again after clinical encounter (and intervention, for the study arm). The total estimated time will be approximately 1 hour since randomization.
Secondary outcomes (1)
Testing Intention
Survey will be used to assess subjects' intention to accept or decline
Measured: Participant will be assessed from the time of randomization and again after clinical encounter (and intervention, for the study arm). The total estimated time will be approximately 1 hour since randomization.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2018
- Study start7 Mar 2018
- Primary completion31 Dec 2019 (estimated)
- Study completion31 Dec 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autosomal Recessive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Wayne State University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Manesha Putra, MD, Wayne State University
- Investigators
- Manesha Putra, MD, Principal investigator, Wayne State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03449225
- Sponsor's protocol ID
- 115217B3E
- Acronym
- CAGEM
- Status last verified
- Apr 2019
- First submitted
- 20 Feb 2018
- Last updated
- 2 May 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 May 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of a Computer-Aided Genetics Education Module (CAGEM) on Screening and Testing for Fetal Chromosome Conditions and Carrier Status: A Clinical Trial
- ClinicalTrials.gov ID
- NCT03449225
- Acronym / sponsor ID
- CAGEM / 115217B3E
- Conditions
- Autosomal Recessive Disorder, Aneuploidy
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Wayne State UniversityUniversity, hospital or other
- Study start
- 7 Mar 2018 (actual)
- Primary completion
- 31 Dec 2019 (estimated)
- Study completion
- 31 Dec 2019 (estimated)
- First posted
- 28 Feb 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A standard part of obstetrical care is offering prenatal genetic screening. Numerous professional guidelines have emphasized the importance of pretest counseling for prenatal genetic screenings. Informed consent includes the optional nature of the test, information on the conditions being screened, possible test results, implication of each result, and the type of test offered (screening or diagnostic). This responsibility falls on the physician in a busy clinic. Technology may be able to address this limitation and give consistent pretest counseling for patients waiting for their appointment. This study is looking to evaluate the use of computer-aided genetics education module for facilitating decision making about prenatal genetic screening and testing for fetal chromosome conditions and carrier status.
Detailed description
Rationale Cytogenetic abnormalities are present in nearly 1% of live births, in approximately 2% of pregnancies in women older than 35 years who undergo prenatal diagnosis, and in fully half of all spontaneous, first-trimester abortions. Genetic counseling and screening for cytogenetic abnormalities are an integral part of routine obstetrical care. There are various screening options and strategy available commercially, including screening for the fetus and parental carrier screening. Currently American College of Obstetrics and Gynecology (ACOG) recommends that all pregnant women should be offered screening for fetal aneuploidy. ACOG also recommends panethnic screening for cystic fibrosis, hemoglobinopathies and spinal muscular atrophy carrier status. For other conditions, glycogen storage diseases and fragile X syndrome, the recommendation currently is to screen based on ethnicity and family history. Without thorough counseling, pregnant women may accept multiple screenings without considering the downstream consequences, including anxiety created by additional, sometimes uncertain, information.
Numerous professional societies guidelines have emphasized the importance of pre-test counseling in this setting due to the delicate and complicated nature of genetic conditions. Along with these guidelines, typically minimal recommended information to be provided during a pre-test counseling was included. Generally it involves, the optional nature of the test, general information about condition tested, nature of testing (screening, carrier screening or diagnostic), testing options, possible testing result, implication of each result, cost and availability of genetic counseling should needed. The responsibility of offering these tests and to perform pre-test counseling lie primarily on the obstetrical care providers and has become more burdensome as the number of testing options expands and also due to limited time for discussion during a prenatal care.
Technology may be able to address these limitations. Various studies have evaluated the use of Computerized Decision Aids (CDAs) in facilitating high-quality decision making in various health related contexts with promising results (17-20). CDAs are generally superior to traditional decision aids such as, paper-based or video-based, due to the possibility to tailor CDAs based on the information provided, the ease of information dissemination and also their interactive features which reinforce participation. This study is looking to evaluate the use of computer-based pre-test education for prenatal cytogenetic abnormalities screening.
Statement of Problem Per professional society guidelines, all women should be offered prenatal screening and/or diagnostic testing for fetal aneuploidy (chromosome conditions such as Down syndrome, trisomy 18, trisomy 13, and sex chromosome abnormalities) during pregnancy. Women should also be offered population-based carrier screening but have the option of expanded carrier screening as well. There are an increasing number of testing and screening options available during pregnancy. The obstetrics provider is primarily responsible for ensuring patients are informed about their options and the benefits, risks, and limits of each. These discussions can be time intensive in a setting where the time available is often limited. As such, there is a need to find alternate ways to educate women about their prenatal testing and screening options.
Objectives The overarching purpose of the full project is to determine whether a computer aided genetics education module can improve pregnant women's knowledge about their options for fetal aneuploidy (chromosome) screening and testing and carrier screening and facilitate informed decision making.
The specific aims of the current study are to:
- To develop a computer-aided genetics education module for prenatal cytogenetic abnormalities screening and testing and carrier screening
- To determine the acceptability of the computer-aided genetics educational module for women presenting for care in an obstetrics clinic
- To determine the feasibility of using the computer-aided genetics educational module in a busy obstetrics clinic
- To assess whether use of the module increases knowledge and enhances informed decision making
- To compare the effectiveness of the computer-aided education module to standard care in terms of knowledge gained and impact on decision making
This study will be done in two phases. Phase 1 will involve evaluating the acceptability of the computer-aided genetics education module. Changes will be made to the module based on the feedback obtained. The revised module will then be used for Phase 2. Phase 2 will involve comparing the effectiveness of the computer-aided genetics education module to standard care.
Methodology
A clinician who has access to the daily clinic patient list will identify patients eligible to participate in the study and notify an onsite study team member. Eligible study participants will then be approached by one of the study team members (either a genetic counselor, a genetic counseling student, a medical student, or a maternal-fetal medicine fellow) and be invited to participate in the study. The potential participant will be given the study information sheet and the study team member will review it with her. If the approached participant agrees to take part, participant will be randomized into one of the two arms of the study-control versus tests arm. Randomization will be performed using Qualtrics platform.
- Control arm: The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables. Once the post-education survey is completed, the participant will be given a $5 gift card for her time. Participation in the study is then complete.
- Test arm: The participant she will be given a digital device on which to access the computer-aided genetics educational module. Prior to accessing the module, the participant will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
- All responses (control and test) will be recorded using a unique participant identification number in order to pair pre- and post-intervention responses. The identifier will not be linked to any identifiable information. Of note, all subjects will receive standard provider counseling after completion of the study module (standard of care).
Phase 1: During Phase 1, The investigators will assess the acceptability of the computer-aided genetics educational module in our target study population. During this initial phase, The investigators will only be doing the test arm of the study. Quantitative and qualitative responses from the pre- and post-surveys will be obtained from batches of 10 samples; the module will then be optimized based on the qualitative feedback and overall results on the knowledge, acceptability, and informed consent questions. This will be repeated until user acceptability reaches 80% of the maximum score.
The computerized educational module has been developed based on counseling points recommended by the American College of Obstetrics and Gynecology and is based on a previous study investigating computer-aided education. The application can be accessed at https://interva-online.mobi/CAGEM/participant/guestLogin.do?packageId=178
Survey Instruments There are three separate survey instruments, all of which have been developed on the Qualtrics survey platform. The pre-education survey instrument is the same for control and test participants and includes basic knowledge questions about genetic testing and screening for chromosome conditions and carrier status. The questions are based on the standard information that should be presented when providing genetic counseling on these topics.
There are two versions of the post-intervention survey. Both versions include knowledge questions (same as pre-test questions) and demographic questions. The surveys differ in that the survey for those taking part in the test arm include questions about the acceptability of the computer-aided genetics educational module.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Arm | No intervention | –The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables. |
| Test Arm | Experimental | Other: Computer-Aided Genetic Education Module• The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Pregnant with gestational age of less than 24 weeks
- Good understanding of spoken English
Key exclusion criteria (1 listed)
- Known history of genetic disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Computer-Aided Genetic Education ModuleSubjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy. | Other | Test Arm |
Primary outcome
Knowledge of Genetics
Time frame: Participant will be assessed from the time of randomization and again after clinical encounter (and intervention, for the study arm). The total estimated time will be approximately 1 hour since randomization.
Survey will be used to assess subjects' knowledge on prenatal genetics
1 secondary outcome
Testing Intention
Time frame: Participant will be assessed from the time of randomization and again after clinical encounter (and intervention, for the study arm). The total estimated time will be approximately 1 hour since randomization.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 May 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Autosomal Recessive Disorder
Enrolling by invitationObservational study
AATD-Liver Scan Study
Alpha-1 Antitrypsin Deficiency, AATD
RecruitingPhase 3
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Autosomal Recessive Polycystic Kidney (ARPKD)
Not yet recruitingPhase 1/2
Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)
Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA)
RecruitingPhase 2
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Acute Leukemia, Severe Aplastic Anemia
RecruitingObservational study
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Manesha Putra, MD principal investigator
Wayne State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Computer-Aided Genetic Education Module in people with Autosomal Recessive Disorder and Aneuploidy, run by Wayne State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 May 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Manesha Putra, MD (7732419231, manesha.putra@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Knowledge of Genetics (time frame: Participant will be assessed from the time of randomization and again after clinical encounter (and intervention, for the study arm). The total estimated time will be approximately 1 hour since randomization.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2019.